HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Toura, I. Articles by Taniguchi, M. Search for Related Content PubMed PubMed Citation Articles by Toura, I. Articles by Taniguchi, M.

Cutting Edge: Inhibition of Experimental Tumor Metastasis by Dendritic Cells Pulsed with -Galactosylceramide¹

Isao Toura^*,, Tetsu Kawano^*, Yasunori Akutsu^*,, Toshinori Nakayama^*, Takenori Ochiai and Masaru Taniguchi^2,*

^* CREST (Core Research for Evolutional Science and Technology) Project and Department of Molecular Immunology, Graduate School of Medicine, School of Medicine, and Second Department of Surgery, School of Medicine, Chiba University, Chiba, Japan

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
A unique lymphoid lineage, V14 NKT cells, bearing an invariant Ag receptor encoded by V14 and J281 gene segments, play crucial roles in various immune responses, including protective immunity against malignant tumors. A specific ligand of V14 NKT cells is determined to be -galactosylceramide (-GalCer) which is presented by the CD1d molecule. Here, we report that dendritic cells (DCs) pulsed with -GalCer effectively induce potent antitumor cytotoxic activity by specific activation of V14 NKT cells, resulting in the inhibition of tumor metastasis in vivo. Moreover, a complete inhibition of B16 melanoma metastasis in the liver was observed when -GalCer-pulsed DCs were injected even 7 days after transfer of tumor cells to syngeneic mice where small but multiple metastatic nodules were already formed. The potential utility of DCs pulsed with -GalCer for tumor immunotherapy is discussed.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
The V14 NKT cell has been recently defined as a novel lymphocyte lineage, characterized by the expression of an invariant Ag receptor encoded by V14 and J281 gene segments (1, 2, 3), and detected in most of the peripheral tissues, including lung, liver, bone marrow, and placenta (4). A glycolipid Ag, -galactosylceramide (-GalCer),³ has been found to be a ligand for V14 NKT cells and specifically presented by a class Ib molecule, CD1d (5, 6, 7), which is well conserved through mammalian evolution and lacks allelic polymorphism (8, 9). Injection of -GalCer inhibits tumor metastasis almost completely in the liver or lung (10), indicating that V14 NKT cells are activated in vivo by the ligand and that the activated V14 NKT cells serve as a critical component of host immunity to tumors.

MHC peptides recognized by tumor-specific CTL are being defined in various mouse and human tumor cells, some of which indeed induce CTLs in vitro and also inhibit tumor growth in vivo (11, 12, 13). These results suggest that tumor-specific peptides are particularly effective for the induction of immune reactions against tumors. It is well established that CTL induction usually follows peptide presentation by MHC class I molecules on APC, and, therefore, APCs pulsed with peptides in vitro can stimulate Ag-specific CTLs when administered in vivo. In fact, dendritic cells (DCs) pulsed with a soluble Ag are able to induce protective antitumor immunity accompanied by tumor-specific CTL induction (14, 15, 16, 17). Since -GalCer specifically activates V14 NKT cells in vitro and in vivo, we address whether DCs pulsed with -GalCer are able to activate V14 NKT cells in vivo and induce protective antitumor immunity in situ.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Mice

V14 NKT mice (RAG-1^-/- V14 transgenic (tg) Vß8.2tg mice) with a C57BL/6 (B6) background were established by mating with RAG-1^-/- Vß8.2tg and RAG-1^-/- V14tg mice as described (5). In V14 NKT mice, only transgenic TCRß (V14tg and Vß8.2tg) was expressed and thus resulted in preferential development of V14 NKT cells with undetectable T cells, NK cells, and B cells (5). RAG-1^-/- mice were kindly provided by Dr. Susumu Tonegawa, MIT, Boston, MA (18). Pathogen-free B6 mice were purchased from Japan SLC (Shizuoka, Japan). All mice used in this study were 8–10 wk old and were maintained in our animal facility under specific pathogen-free conditions.

-Galactosylceramide

-Galactosylceramide ((2S,3S,4R)-1-O-(-D-galactopyranosyl)-N-hexacosanoyl-2-amino-1,3,4-octadecanetriol; -GalCer) was provided by Kirin Brewery (Gunma, Japan) and prepared as previously described (5, 10).

Preparation of DCs pulsed with -GalCer

DCs were prepared from spleen of B6 mice according to the methods of Crowly et al. (5, 19). Briefly, spleens were treated with collagenase type III (400 U/ml; Worthington Biochemical, Freehold, NJ) for 20 min at 37°C in 5% CO₂ and then disrupted on a metal screen. Resulting single cells were loaded on a dense BSA (Pentex Path-O-Cyte 4; Bayer, IL) and centrifuged at 1500 x g for 30 min at 4°C. The low density fraction was further applied to plastic culture dishes (Falcon, Franklin Lakes, NJ) for 90 min at 37°C in 5% CO₂. Adherent cells were pulsed with -GalCer (100 ng/ml in 0.025% polysolvate 20) or control vehicle (0.025% polysolvate 20) overnight at 37°C. After washing extensively, nonadherent cells were used as -GalCer-pulsed DCs.

⁵¹Cr release cytotoxicity assay

The ⁵¹Cr release assay was conducted by a standard method as described (10). In brief, -GalCer-pulsed DCs were injected i.v. into normal B6 or V14 NKT mice, and, 24 h later, the cytotoxic activity of their spleen cells was assessed on YAC-1 cells, B16 melanoma cells, or Colon 26 cells labeled with 100 µCi of sodium chromate (⁵¹Cr; Amersham Pharmacia Biotech, Uppsala, Sweden) for 1 h at 37°C. Effector cells (3 x 10⁵) were mixed with 1 x 10⁴ tumor cells at indicated E:T ratios in a 96-well round-bottom plate (Falcon, Lincoln Park, NJ) in 150 µl of complete media at 37°C in 5% CO₂. Four hours later, released ⁵¹Cr was measured. The percentage cytotoxicity was calculated, and mean values were shown with SDs as described (10).

Tumor metastasis model

B16 melanoma cells (3 x 10⁶) or Lewis lung carcinoma (LLC) cells (4 x 10⁵) were inoculated into B6 mice on day 0 via spleen for liver metastasis or via tail vein for lung metastasis, respectively. In the case of liver metastasis model, mice were sacrificed on day 14, and the metastasis of B16 melanoma cells in the liver was evaluated by measuring the amount of melanoma Ag (G_M3 ganglioside) as described (20). For the lung metastasis model, mice were sacrificed on day 18, and the number of metastatic nodules of LLC was counted under a light microscope. Three to five mice were used for each group in every experiment. -GalCer-pulsed DCs were transferred i.v.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Activation of V14 NKT cells by -GalCer-pulsed DCs in vivo

We have reported that murine and human NKT cells recognize -GalCer in a CD1d-restricted fashion (5, 6, 21, 22, 23). Moreover, the administration of -GalCer activates V14 NKT cells in vivo and induces cytotoxic activity against various tumor cells in an NK-like fashion (5, 10). Thus, we expected efficient activation of resting V14 NKT cells with -GalCer-pulsed DCs in vivo. To test this assumption, graded numbers of -GalCer-pulsed DCs were i.v. administered into normal B6 mice, and their cytotoxic activity in the spleen cells was evaluated by ⁵¹Cr release assay (Fig. 1A). A significant cytotoxicity against YAC-1 cells was induced by more than 2 x 10⁵ cells of -GalCer-, but not vehicle-, pulsed DCs. This suggests that -GalCer-pulsed DCs indeed activate V14 NKT cells in vivo. To confirm the data in Fig. 1A, V14 NKT mice bearing only V14 NKT cells were i.v. administered 1 x 10⁶ -GalCer-pulsed DCs. A potent antitumor cytotoxicity against B16 melanoma and Colon 26 cells was detected only when -GalCer-, but not vehicle-, pulsed DCs were injected (Fig. 1B).

View larger version (15K): [in this window] [in a new window]   FIGURE 1. Activation of V14 NKT cells in vivo by administration of -GalCer-pulsed DCs. A, B6 mice were i.v. administered 1 x 106 vehicle-pulsed DCs (), 2 x 105 -GalCer-pulsed DCs (), or 1 x 106 -GalCer-pulsed DCs (•) of B6 mice. Twenty four hours after the administration, their cytotoxicity was examined on YAC-1 cells at indicated E:T ratios. B, -GalCer-pulsed (•) or vehicle-pulsed () DCs (3 x 105) from RAG-1-/- mice were transferred i.v. into V14 NKT mice. Their cytotoxicity was assayed 24 h after DC transfer on B16 melanoma and Colon 26 cells.

Inhibition of tumor metastasis by -GalCer-pulsed DCs

To test whether the transfer of -GalCer-pulsed DCs induces inhibition of tumor metastasis as a consequence of in vivo activation of V14 NKT cells, -GalCer- or vehicle-pulsed DCs were i.v. transferred into normal B6 mice on the next day (day 1) after intrasplenic injection of tumor cells on day 0 (day 0). Hepatic metastasis of B16 melanoma cells was inhibited by transfer of -GalCer-pulsed DCs in a dose-dependent manner (Fig. 2A). No metastatic nodules were detected in the liver with injection of -GalCer-, but not vehicle-, pulsed DCs (3 x 10⁶ cells) macroscopically (Fig. 2A) and microscopically (data not shown). No significant melanoma Ag was detected by quantitation of B16 melanoma Ag, GM3 ganglioside, when 3 x 10⁶ -GalCer-pulsed DCs were transferred (Fig. 2A, right). The inhibitory effect of tumor metastasis was also observed in a lung metastatic model using LLC cells. A single i.v. injection of -GalCer-pulsed DCs (3 x 10⁶), but not vehicle-pulsed DCs, induced a complete inhibition of lung metastasis of LLC (Fig. 2B).

View larger version (30K): [in this window] [in a new window]   FIGURE 2. Inhibition of tumor metastasis by -GalCer-pulsed DCs. The antitumor effect of -GalCer-pulsed DCs was evaluated using two different metastasis models: liver metastasis of B16 melanoma (A) and lung metastasis of LLC (B). Tumor cells were inoculated into B6 mice on day 0. One day after the inoculation, indicated numbers of -GalCer-pulsed DCs were transferred i.v. Representative photographic views of metastasized organs are shown. The quantitative analysis of tumor metastasis was performed by measuring the amount of melanoma Ag, GM3 ganglioside in the liver (A, right), or the number of metastatic nodules in the lung (B, right). The levels were indicated as filled or open bars in -GalCer-pulsed DCs or control vehicle-DCs, respectively. Five mice were used in each group, and mean values with SDs are shown.

Eradication of established metastatic foci by -GalCer-pulsed DCs

The next experiments were designed to know whether the -GalCer-pulsed DCs were also effective on established tumors. To address this question, -GalCer-pulsed DCs were i.v. transferred into B6 mice bearing multiple metastatic tumor foci in the liver. First, the levels of metastasis of B16 melanoma cells in the liver were monitored, and representative results on days 5, 7, and 9 are shown in Fig. 3A. On day 5, no metastatic foci were observed macroscopically, whereas numerous single melanoma cells were microscopically identified in a section of the liver (arrowheads). On day 7, however, numerous metastatic foci were detected both macroscopically and microscopically. Their sizes were increased, and some were fused with each other on day 9. The sizes of tumor foci on day 7 were in the range between 0.1 and 0.5 mm in diameter, and about 100 foci were detected macroscopically (Fig. 3B). Consequently, we started to transfer 3 x 10⁶ vehicle- or -GalCer-pulsed DCs on day 7, on day 9, and on day 11 and continued every other day until day 13. We chose the dose of DCs (3 x 10⁶) that showed significant curative effects, as shown in Fig. 2. As we anticipated, almost complete eradication of established metastatic foci was observed when the transfer of -GalCer-pulsed DCs (3 x 10⁶) started on day 7 (Fig. 3C). Little effect was observed whether the transfer started on day 9 or day 11. These results strongly indicated that -GalCer-pulsed DCs exerted a strong antitumor effect, resulting in the regression of the established metastatic nodules. Finally, to evaluate the efficacy of -GalCer-pulsed DCs, we treated the melanoma-bearing B6 mice with simple injection of -GalCer (100 µg/kg) started on day 1, 3, 5, and 7 (Fig. 3D). In contrast to the treatment with -GalCer-pulsed DCs, significant antitumor effect was observed only when the -GalCer injection started on day 1 and on day 3, suggesting a significant advantage for the use of -GalCer-pulsed DCs in the eradication of the established tumor metastasis.

View larger version (31K): [in this window] [in a new window]   FIGURE 3. Regression of established metastatic tumors by -GalCer-pulsed DCs. The macroscopic and microscopic views of tumor foci (A) and their sizes and numbers on day 7 and day 9 are shown (B). Arrows in A indicate micrometastasis of B16 melanoma cells. C, Effects of i.v. administration of -GalCer-pulsed DCs on established B16 melanoma foci were assessed. B6 DCs (3 x 106) were pulsed with vehicle (open bar) or -GalCer (filled bar) and then i.v. transferred into tumor-bearing B6 mice. The transfer of pulsed DCs started on day 7, day 9, or day 11. The same numbers of pulsed DCs were injected every other day until day 13. All mice were sacrificed on day 14. Representative photographic views are shown. Three mice are used in each group, and mean values with SDs are shown. The results of two independent experiments were similar. D, Tumor-bearing B6 mice were treated with i.v. injection of vehicle (open bar) or -GalCer (100 µg/kg; filled bar) in vivo, which started on days 1, 3, 5, and 7 and continued every other day until day 13. The amounts of melanoma Ag were measured and are depicted as bars.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

-GalCer is presented by a monomorphic CD1d on DCs and recognized by the invariant V14 NKTCR (5, 6). Injection of -GalCer in vivo, only when started soon after tumor cell transfer, induces antitumor activity against metastatic tumors macroscopically (5) and microscopically (24). This indicates that it takes a longer time for DCs to present -GalCer, to activate V14 NKT cells, and to induce antitumor activities in vivo. However, -GalCer-pulsed DCs are more effective than the direct injection of -GalCer, as evidenced by the results showing that established metastatic foci can be regressed by -GalCer-pulsed DCs but not by -GalCer injection (Fig. 3, C and D).

The manipulation of tumor immunity is totally dependent on the induction of tumor-specific cytotoxicity, which is known to be mediated by CTL (14, 15, 16). Thus, many efforts have been made to identify tumor-specific peptides, including human malignant melanoma-related Ags, such as gp100 (25), melanoma antigen recognized by T cells-1 (MART-1 (11)), tyrosinase (11), and melanoma-associated antigen-1 (MAGE-1) and MAGE-3 (26). Indeed, some of these peptides have shown a successful induction of antimelanoma immunity (12). Furthermore, various tumor-associated Ags or specific peptides, such as PSA (27), papilloma virus protein (28), receptor for advanced glycosylation and products-1 (RAGE-1 (29)), and tumor associated mucin 1 (MUC1) (30, 31), are identified, and their ability to generate CTL is elucidated.

However, there are several critical problems for the application of tumor peptide therapy to cancer patients. For example, since MHC haplotypes in individuals are different, tumor peptides derived from a certain MHC molecule cannot be applied to other patients with different MHC. Moreover, the MHC level is reported to be different in the region of tumor tissues (32, 33), and, thus, all tumor cells cannot be targets of CTL. In this view, the CD1d/-GalCer and NKT cell system appears to be ideal to circumvent these problems, because V14 NKT cells effectively kill tumors with low or no expression of MHC.

The second important point is that -GalCer-pulsed DCs can induce antitumor activity in vivo within 24 h after cell transfer (Fig. 1B). Our previous study using RNase protection analysis shows that V14 NKT cells are expanded in the peripheral tissues in situ (34), suggesting no requirement of clonal expansion of V14 NKT cells to exert antitumor functions. Thus, only specific activation of resting V14 NKT cells is required. This is distinct from the peptide-mediated antitumor immunity, in which the in vivo induction and expansion of tumor peptide-specific CTLs are indispensable, because it requires a certain period of time and also needs booster immunization to expand specific CTL clones in vivo to obtain sufficient antitumor effects.

In summary, the unique antitumor immune system comprised with CD1d and V14 NKT cells in mice is specifically driven by a single glycolipid Ag, -GalCer. Since -GalCer works as a ligand for V24 NKT cells in the human NKT system (21, 22, 23), our findings suggest the potential utility of the CD1d/NKT system for cancer immunotherapy and might open a new window for inclusive cancer therapy in humans.

	Acknowledgments

 
We thank Kirin Brewery Co. Ltd. for providing us with glycolipid reagents, and Ms Hiroko Tanabe for secretarial work.

	Footnotes

 
¹ This work was supported in part by a Grant-in-Aid for Scientific Research on Priority Areas (06282103) from the Ministry of Education, Culture, Sports, and Science, Japan, and by a grant from Taisho Pharmaceutical Company, Japan.

² Address correspondence and reprint requests to Dr. Masaru Taniguchi, Department of Molecular Immunology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. E-mail address:

³ Abbreviations used in this paper: -GalCer, -galactosylceramide; DC, dendritic cell; LLC, Lewis lung cancer; tg, transgenic; B6, C57BL/6.

Received for publication May 25, 1999. Accepted for publication July 6, 1999.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Koseki, H., K. Imai, F. Nakayama, T. Sado, K. Moriwaki, M. Taniguchi. 1990. Homogenous junctional sequence of the V14⁺ T-cell antigen receptor chain expanded in unprimed mice. Proc. Natl. Acad. Sci. USA 87:5248.[Abstract/Free Full Text]
2. Lantz, O., A. Bendelac. 1994. An invariant T cell receptor chain is used by a unique subset of major histocompatibility complex class I-specific CD4⁺ and CD4^-8^- T cells in mice and humans. J. Exp. Med. 180:1097.[Abstract/Free Full Text]
3. Makino, Y., R. Kanno, T. Ito, K. Higashino, M. Taniguchi. 1995. Predominant expression of invariant V14⁺ TCR chain in NK1.1⁺ T cell populations. Int. Immunol. 7:1157.[Abstract/Free Full Text]
4. Makino, Y., H. Koseki, Y. Adachi, T. Akasaka, K. Tsuchida, M. Taniguchi. 1994. Extrathymic differentiation of a T cell bearing invariant V14J 281 TCR. Int. Rev. Immunol. 11:31.[Medline]
5. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, H. Koseki, M. Taniguchi. 1997. CD1d-restricted and TCR-mediated activation of V14 NKT cells by glycosylceramides. Science 278:1626.[Abstract/Free Full Text]
6. Burdin, N., L. Brossay, Y. Koezuka, S. T. Smiley, M. J. Grusby, M. Gui, M. Taniguchi, K. Hayakawa, M. Kronenberg. 1998. Selective ability of mouse CD1 to present glycolipids: -galactosylceramide specifically stimulates V14⁺ NK T lymphocytes. J. Immunol. 161:3271.[Abstract/Free Full Text]
7. Brossay, L., N. Burdin, S. Tangri, M. Kronenberg. 1998. Antigen-presenting function of mouse CD1: one molecule with two different kinds of antigenic ligands. Immunol. Rev. 163:139.[Medline]
8. Porcelli, S. A.. 1995. The CD1 family: a third lineage of antigen-presenting molecules. Adv. Immunol. 59:1.[Medline]
9. Porcelli, S. A., B. W. Segelke, M. Sugita, I. A. Wilson, M. B. Brenner. 1998. The CD1 family of lipid antigen-presenting molecules. Immunol. Today 19:362.[Medline]
10. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, H. Sato, E. Kondo, M. Harada, H. Koseki, T. Nakayama, Y. Tanaka, M. Taniguchi. 1998. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated V14 NKT cells. Proc. Natl. Acad. Sci. USA 95:5690.[Abstract/Free Full Text]
11. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P. F. Robbins, L. Rivoltini, J. R. Yannelli, E. Appella, S. A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347.[Abstract/Free Full Text]
12. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, et al 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321.[Medline]
13. Timmerman, J. M., R. Levy. 1999. Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med. 50:507.[Medline]
14. Paglia, P., C. Chiodoni, M. Rodolfo, M. P. Colombo. 1996. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183:317.[Abstract/Free Full Text]
15. Celluzzi, C. M., J. I. Mayordomo, W. J. Storkus, M. T. Lotze, Jr L. D. Falo. 1996. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J. Exp. Med. 183:283.[Abstract/Free Full Text]
16. Mayordomo, J. I., T. Zorina, W. J. Storkus, L. Zitvogel, C. Celluzzi, L. D. Falo, C. J. Melief, S. T. Ildstad, W. M. Kast, A. B. Deleo, et al 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1:1297.[Medline]
17. Hsu, F. J., C. Benike, F. Fagnoni, T. M. Liles, D. Czerwinski, B. Taidi, E. G. Engleman, R. Levy. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:52.[Medline]
18. Mombaerts, P., J. Iacomini, R. S. Johnson, K. Herrup, S. Tonegawa, V. E. Papaioannou. 1992. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68:869.[Medline]
19. Crowley, M., K. Inaba, M. Witmer-Pack, R. M. Steinman. 1989. The cell surface of mouse dendritic cells: FACS analyses of dendritic cells from different tissues including thymus. Cell. Immunol. 118:108.[Medline]
20. Cui, J., T. Shin, T. Kawano, H. Sato, E. Kondo, I. Toura, Y. Kaneko, H. Koseki, M. Kanno, M. Taniguchi. 1997. Requirement for V14 NKT cells in IL-12-mediated rejection of tumors. Science 278:1623.[Abstract/Free Full Text]
21. Brossay, L., M. Chioda, N. Burdin, Y. Koezuka, G. Casorati, P. Dellabona, M. Kronenberg. 1998. CD1d-mediated recognition of an -galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J. Exp. Med. 188:1521.[Abstract/Free Full Text]
22. Spada, F. M., Y. Koezuka, S. A. Porcelli. 1998. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J. Exp. Med. 188:1529.[Abstract/Free Full Text]
23. Kawano, T., Y. Tanaka, E. Shimizu, Y. Kaneko, N. Kamata, H. Sato, H. Osada, S. Sekiya, T. Nakayama, M. Taniguchi. 1999. A novel recognition motif of human NKT cell receptors for a glycolipid ligand. Int. Immunol. 11:881.[Abstract/Free Full Text]
24. Nakagawa, R., K. Motoki, H. Ueno, R. Iijima, H. Nakamura, E. Kobayashi, A. Shimosaka, Y. Koezuka. 1998. Treatment of hepatic metastasis of the Colon 26 adenocarcinoma with an -galactosylceramide, KRN7000. Cancer Res. 58:1202.[Abstract/Free Full Text]
25. Bakker, A. B., M. W. Schreurs, A. J. de Boer, Y. Kawakami, S. A. Rosenberg, G. J. Adema, C. G. Figdor. 1994. Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes. J. Exp. Med. 179:1005.[Abstract/Free Full Text]
26. van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643.[Abstract/Free Full Text]
27. Correale, P., K. Walmsley, C. Nieroda, S. Zaremba, M. Zhu, J. Schlom, K. Y. Tsang. 1997. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J. Natl. Cancer Inst. 89:293.[Abstract/Free Full Text]
28. Stauss, H. J., H. Davies, E. Sadovnikova, B. Chain, N. Horowitz, C. Sinclair. 1992. Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in human papilloma virus. Proc. Natl. Acad. Sci. USA 89:7871.[Abstract/Free Full Text]
29. Flad, T., B. Spengler, H. Kalbacher, P. Brossart, D. Baier, R. Kaufmann, P. Bold, S. Metzger, M. Bluggel, H. E. Meyer, B. Kurz, C. A. Muller. 1998. Direct identification of major histocompatibility complex class I-bound tumor-associated peptide antigens of a renal carcinoma cell line by a novel mass spectrometric method. Cancer Res. 58:5803.[Abstract/Free Full Text]
30. Ioannides, C. G., B. Fisk, K. R. Jerome, T. Irimura, J. T. Wharton, O. J. Finn. 1993. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J. Immunol. 151:3693.[Abstract]
31. Jerome, K. R., N. Domenech, O. J. Finn. 1993. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J. Immunol. 151:1654.[Abstract]
32. Bodmer, W. F., M. J. Browning, P. Krausa, A. Rowan, D. C. Bicknell, J. G. Bodmer. 1993. Tumor escape from immune response by variation in HLA expression and other mechanisms. Ann. NY Acad. Sci. 690:42.[Medline]
33. Maeurer, M. J., S. M. Gollin, D. Martin, W. Swaney, J. Bryant, C. Castelli, P. Robbins, G. Parmiani, W. J. Storkus, M. T. Lotze. 1996. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with down-regulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J. Clin. Invest. 98:1633.[Medline]
34. Koseki, H., H. Asano, T. Inaba, N. Miyashita, K. Moriwaki, K. F. Lindahl, Y. Mizutani, K. Imai, M. Taniguchi. 1991. Dominant expression of a distinctive V14⁺ T-cell antigen receptor chain in mice. Proc. Natl. Acad. Sci. USA 88:7518.[Abstract/Free Full Text]

This article has been cited by other articles:

				E. Germanov, L. Veinotte, R. Cullen, E. Chamberlain, E. C. Butcher, and B. Johnston Critical Role for the Chemokine Receptor CXCR6 in Homeostasis and Activation of CD1d-Restricted NKT Cells J. Immunol., July 1, 2008; 181(1): 81 - 91. [Abstract] [Full Text] [PDF]

				J. A. Berzofsky and M. Terabe NKT Cells in Tumor Immunity: Opposing Subsets Define a New Immunoregulatory Axis J. Immunol., March 15, 2008; 180(6): 3627 - 3635. [Abstract] [Full Text] [PDF]

				K. Shimizu, Y. Kurosawa, M. Taniguchi, R. M. Steinman, and S.-i. Fujii Cross-presentation of glycolipid from tumor cells loaded with {alpha}-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells J. Exp. Med., October 29, 2007; 204(11): 2641 - 2653. [Abstract] [Full Text] [PDF]

				J. Okajo, Y. Kaneko, Y. Murata, T. Tomizawa, C. Okuzawa, Y. Saito, Y. Kaneko, T. Ishikawa-Sekigami, H. Okazawa, H. Ohnishi, et al. Regulation by Src Homology 2 Domain-Containing Protein Tyrosine Phosphatase Substrate-1 of {alpha}-Galactosylceramide-Induced Antimetastatic Activity and Th1 and Th2 Responses of NKT Cells J. Immunol., May 15, 2007; 178(10): 6164 - 6172. [Abstract] [Full Text] [PDF]

				H. J.J. van der Vliet, S. P. Balk, and M. A. Exley Natural Killer T Cell-Based Cancer Immunotherapy. Clin. Cancer Res., October 15, 2006; 12(20): 5921 - 5923. [Full Text] [PDF]

				S Nagaraj, C Ziske, J Strehl, D Messmer, T Sauerbruch, and I. Schmidt-Wolf Dendritic cells pulsed with alpha-galactosylceramide induce anti-tumor immunity against pancreatic cancer in vivo Int. Immunol., August 1, 2006; 18(8): 1279 - 1283. [Abstract] [Full Text] [PDF]

				M. Terabe, J. Swann, E. Ambrosino, P. Sinha, S. Takaku, Y. Hayakawa, D. I. Godfrey, S. Ostrand-Rosenberg, M. J. Smyth, and J. A. Berzofsky A nonclassical non-V{alpha}14J{alpha}18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance J. Exp. Med., December 19, 2005; 202(12): 1627 - 1633. [Abstract] [Full Text] [PDF]

				K. Minami, Y. Yanagawa, K. Iwabuchi, N. Shinohara, T. Harabayashi, K. Nonomura, and K. Onoe Negative feedback regulation of T helper type 1 (Th1)/Th2 cytokine balance via dendritic cell and natural killer T cell interactions Blood, September 1, 2005; 106(5): 1685 - 1693. [Abstract] [Full Text] [PDF]

				M. Biburger and G. Tiegs {alpha}-Galactosylceramide-Induced Liver Injury in Mice Is Mediated by TNF-{alpha} but Independent of Kupffer Cells J. Immunol., August 1, 2005; 175(3): 1540 - 1550. [Abstract] [Full Text] [PDF]

				M. J. Smyth, M. E. Wallace, S. L. Nutt, H. Yagita, D. I. Godfrey, and Y. Hayakawa Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer J. Exp. Med., June 20, 2005; 201(12): 1973 - 1985. [Abstract] [Full Text] [PDF]

				D. H. Chang, K. Osman, J. Connolly, A. Kukreja, J. Krasovsky, M. Pack, A. Hutchinson, M. Geller, N. Liu, R. Annable, et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of {alpha}-galactosyl-ceramide loaded mature dendritic cells in cancer patients J. Exp. Med., May 2, 2005; 201(9): 1503 - 1517. [Abstract] [Full Text] [PDF]

				T. Hanada, K. Tanaka, Y. Matsumura, M. Yamauchi, H. Nishinakamura, H. Aburatani, R. Mashima, M. Kubo, T. Kobayashi, and A. Yoshimura Induction of Hyper Th1 Cell-Type Immune Responses by Dendritic Cells Lacking the Suppressor of Cytokine Signaling-1 Gene J. Immunol., April 1, 2005; 174(7): 4325 - 4332. [Abstract] [Full Text] [PDF]

				A. Ishikawa, S. Motohashi, E. Ishikawa, H. Fuchida, K. Higashino, M. Otsuji, T. Iizasa, T. Nakayama, M. Taniguchi, and T. Fujisawa A Phase I Study of {alpha}-Galactosylceramide (KRN7000)-Pulsed Dendritic Cells in Patients with Advanced and Recurrent Non-Small Cell Lung Cancer Clin. Cancer Res., March 1, 2005; 11(5): 1910 - 1917. [Abstract] [Full Text] [PDF]

				Y. Lin, T. J. Roberts, P. M. Spence, and R. R. Brutkiewicz Reduction in CD1d expression on dendritic cells and macrophages by an acute virus infection J. Leukoc. Biol., February 1, 2005; 77(2): 151 - 158. [Abstract] [Full Text] [PDF]

				G. Gerlini, A. Tun-Kyi, C. Dudli, G. Burg, N. Pimpinelli, and F. O. Nestle Metastatic Melanoma Secreted IL-10 Down-Regulates CD1 Molecules on Dendritic Cells in Metastatic Tumor Lesions Am. J. Pathol., December 1, 2004; 165(6): 1853 - 1863. [Abstract] [Full Text] [PDF]

				J. E. Gumperz CD1d-restricted "NKT" cells and myeloid IL-12 production: an immunological crossroads leading to promotion or suppression of effective anti-tumor immune responses? J. Leukoc. Biol., August 1, 2004; 76(2): 307 - 313. [Abstract] [Full Text] [PDF]

				M. Nieda, M. Okai, A. Tazbirkova, H. Lin, A. Yamaura, K. Ide, R. Abraham, T. Juji, D. J. Macfarlane, and A. J. Nicol Therapeutic activation of V{alpha}24+V{beta}11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity Blood, January 15, 2004; 103(2): 383 - 389. [Abstract] [Full Text] [PDF]

				L. T. van den Broeke, E. Daschbach, E. K. Thomas, G. Andringa, and J. A. Berzofsky Dendritic Cell-Induced Activation of Adaptive and Innate Antitumor Immunity J. Immunol., December 1, 2003; 171(11): 5842 - 5852. [Abstract] [Full Text] [PDF]

				B. Gansuvd, W. J. Hubbard, A. Hutchings, F. T. Thomas, J. Goodwin, S. B. Wilson, M. A. Exley, and J. M. Thomas Phenotypic and Functional Characterization of Long-Term Cultured Rhesus Macaque Spleen-Derived NKT Cells J. Immunol., September 15, 2003; 171(6): 2904 - 2911. [Abstract] [Full Text] [PDF]

				Y. Hayakawa, S. Rovero, G. Forni, and M. J. Smyth {alpha}-Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis PNAS, August 5, 2003; 100(16): 9464 - 9469. [Abstract] [Full Text] [PDF]

				T. Azuma, T. Takahashi, A. Kunisato, T. Kitamura, and H. Hirai Human CD4+ CD25+ Regulatory T Cells Suppress NKT Cell Functions Cancer Res., August 1, 2003; 63(15): 4516 - 4520. [Abstract] [Full Text] [PDF]

				S. Gillessen, Y. N. Naumov, E. E. S. Nieuwenhuis, M. A. Exley, F. S. Lee, N. Mach, A. D. Luster, R. S. Blumberg, M. Taniguchi, S. P. Balk, et al. CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion PNAS, July 22, 2003; 100(15): 8874 - 8879. [Abstract] [Full Text] [PDF]

				S.-i. Fujii, K. Shimizu, C. Smith, L. Bonifaz, and R. M. Steinman Activation of Natural Killer T Cells by {alpha}-Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein J. Exp. Med., July 21, 2003; 198(2): 267 - 279. [Abstract] [Full Text] [PDF]

				M. V. Dhodapkar, M. D. Geller, D. H. Chang, K. Shimizu, S.-I. Fujii, K. M. Dhodapkar, and J. Krasovsky A Reversible Defect in Natural Killer T Cell Function Characterizes the Progression of Premalignant to Malignant Multiple Myeloma J. Exp. Med., June 16, 2003; 197(12): 1667 - 1676. [Abstract] [Full Text] [PDF]

				M. Capone, D. Cantarella, J. Schumann, O. V. Naidenko, C. Garavaglia, F. Beermann, M. Kronenberg, P. Dellabona, H. R. MacDonald, and G. Casorati Human Invariant V{alpha}24-J{alpha}Q TCR Supports the Development of CD1d-Dependent NK1.1+ and NK1.1- T Cells in Transgenic Mice J. Immunol., March 1, 2003; 170(5): 2390 - 2398. [Abstract] [Full Text] [PDF]

				D. Stober, I. Jomantaite, R. Schirmbeck, and J. Reimann NKT Cells Provide Help for Dendritic Cell-Dependent Priming of MHC Class I-Restricted CD8+ T Cells In Vivo J. Immunol., March 1, 2003; 170(5): 2540 - 2548. [Abstract] [Full Text] [PDF]

				S. L. H. van Dommelen, H. A. Tabarias, M. J. Smyth, and M. A. Degli-Esposti Activation of Natural Killer (NK) T Cells during Murine Cytomegalovirus Infection Enhances the Antiviral Response Mediated by NK Cells J. Virol., February 1, 2003; 77(3): 1877 - 1884. [Abstract] [Full Text] [PDF]